“J-Pharma Enters into Non-Binding Term Sheet with European Biotech Company for JPH034” — Aiming to Enter into a License Agreement for Global Development and Commercialization —

J-Pharma Transitions to an Executive Officer Structure as Development Pipeline Advances — Shinya Hirata Appointed as New Executive Officer —

J-Pharma’s LAT1 Inhibitor Development Included in University Office of Technology Commercialization’s FY2026 Annual Report — Report Highlights Progress in Clinical Development—